Peters, Oliver

PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment

(ADNI), A. D. N. I., Kleineidam, L., Chouraki, V., Próchnicki, T., van der Lee, S. J., Madrid-Márquez, L., Wagner-Thelen, H., Karaca, I., Weinhold, L., Wolfsgruber, S., et al. (2020) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 62

Genome-wide association study of vascular dementia

Schrijvers, E. M. C., Schürmann, B., Koudstaal, P. J., van den Bussche, H., Van Duijn, C. M., Hentschel, F., Heun, R., Hofman, A., Jessen, F., Kölsch, H., et al. (2012) · Stroke

Dementia and Cognitive Impairment ResearchGenetic Associations and Epidemiology

Cited by 61

Structural integrity in subjective cognitive decline, mild cognitive impairment and Alzheimer’s disease based on multicenter diffusion tensor imaging

The DELCODE Study Group, Brueggen, K., Dyrba, M., Cardenas-Blanco, A., Schneider, A., Fliessbach, K., Buerger, K., Janowitz, D., Peters, O., Menne, F., et al. (2019) · Journal of Neurology

Dementia and Cognitive Impairment ResearchAdvanced Neuroimaging Techniques and Applications

Cited by 51

SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease

Ramirez, A., van der Flier, W. M., Herold, C., Ramonet, D., Heilmann, S., Lewczuk, P., Popp, J., Lacour, A., Drichel, D., Louwersheimer, E., et al. (2014) · Human Molecular Genetics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 49

Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project

Initiative, F. T. A. D. N., van Maurik, I. S., Slot, R. E. R., Verfaillie, S. C. J., Zwan, M. D., Bouwman, F. H., Prins, N. D., Teunissen, C. E., Scheltens, P., Barkhof, F., et al. (2019) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 47

Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer’s type

Martino Adami, P. V., Orellana, A., García, P., Kleineidam, L., Alarcón-Martín, E., Montrreal, L., Aguilera, N., Espinosa, A., Abdelnour, C., Rosende-Roca, M., et al. (2022) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 46

Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical Trial

Maier, F., Spottke, A., Bach, J.-P., Bartels, C., Buerger, K., Dodel, R., Fellgiebel, A., Fliessbach, K., Frölich, L., Hausner, L., et al. (2020) · JAMA Network Open

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 46

Cognitive Behavioral Therapy for Late-Life Depression (CBTlate): Results of a Multicenter, Randomized, Observer-Blinded, Controlled Trial

Dafsari, F. S., Bewernick, B., Böhringer, S., Domschke, K., Elsaesser, M., Löbner, M., Luppa, M., Preis, L., Püsken, J., Schmitt, S., et al. (2023) · Psychotherapy and Psychosomatics

Psychotherapy Techniques and ApplicationsAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 30

Association of cholinergic basal forebrain volume and functional connectivity with markers of inflammatory response in the Alzheimer’s disease spectrum

Teipel, S. J., Dyrba, M., Ballarini, T., Brosseron, F., Bruno, D., Buerger, K., Cosma, N.-C., Dechent, P., Dobisch, L., Düzel, E., et al. (2022) · Journal of Alzheimer s Disease

Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

Cited by 20

Consensus meta-analysis of genome-wide association studies for Alzheimer’s disease and related dementias

EADB, Bellenguez, C., Castillo Morales, A., Amin, N., van der Lee, S. J., Muntaner, M., Parveen, K., Küçükali, F., Grenier-Boley, B., Heikkinen, S., et al. (2026) · Nature Genetics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 7